title: Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma.
authors.affiliation: Dana-Farber/Brigham and Women's Cancer Center, Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts (B.M.A.); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (L.T.); Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts (L.T.).
authors.forename: Brian M
authors.initials: BM
authors.lastname: Alexander
authors.affiliation: Dana-Farber/Brigham and Women's Cancer Center, Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts (B.M.A.); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (L.T.); Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts (L.T.).
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Trippa
mesh_terms: D005909:Glioblastoma / Q000401:mortality*; D006801:Humans
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4562-8
references.pmid: 17876010
references.citation: J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9
references.pmid: 19903805
references.citation: N Engl J Med. 2014 Feb 20;370(8):699-708
references.pmid: 24552317
references.citation: N Engl J Med. 2014 Feb 20;370(8):709-22
references.pmid: 24552318
references.citation: Neuro Oncol. 2015 Aug;17(8):1106-13
references.pmid: 25568226
references.citation: Neuro Oncol. 2014 May;16(5):696-706
references.pmid: 24335699